Cipla Testosterone and Other Sexual Health Products
Cipla’s urology portfolio includes products and therapy areas related to hypogonadism and sexual dysfunction, but testosterone products should be separated from erectile-dysfunction medicines such as sildenafil and tadalafil. Testosterone replacement products are a different drug category, have different regulatory controls, and are not interchangeable with PDE5 inhibitors.
Consumers may encounter searches and product references such as “Cipla testosterone,” “Cipla testosterone tablets,” and “testosterone tablets Cipla price.” Current product records are more specific than those broad phrases. Current U.S. authoritative sources verify Cipla USA testosterone products in injectable and topical solution forms. A current authoritative U.S. source for a Cipla USA testosterone tablet product was not identified, so no current tablet price or availability claim is made.
Cipla and Sexual-Health Medicines
Cipla’s current corporate therapy information identifies urology as an important area and specifically includes hypogonadism and sexual dysfunction among the conditions in that portfolio. At the product level, however, a user still needs to distinguish three different questions:
- Is the product a testosterone replacement product?
- Is it a PDE5 inhibitor such as sildenafil or tadalafil?
- Which exact formulation and market is being discussed?
Those distinctions matter because similar product questions do not imply similar treatment or labeling. A user researching erectile dysfunction may encounter both testosterone-related content and PDE5-inhibitor content, but they refer to different product categories.
Testosterone Products Associated With Cipla
Current DailyMed records verify a Cipla USA testosterone cypionate injection product. One active record lists testosterone cypionate injection, USP at 200 mg/mL, packaged under Cipla USA Inc., with an ANDA marketing category. The label identifies intramuscular administration and controlled-substance Schedule III status in the United States.
DailyMed also verifies a Cipla USA testosterone topical solution. The current record lists testosterone at 30 mg per 1.5 mL, identifies the dosage form as a topical solution, and links the product to ANDA 209533. Current patient labeling includes precautions about transfer of topical testosterone to other people through skin contact.
These are specific current U.S. products. They do not establish that every historical Cipla testosterone brand or dosage form remains marketed today.
Testosterone Tablets, Injections and Topical Forms
The phrase “Cipla testosterone tablets” appears online, but a current authoritative U.S. source for a Cipla testosterone tablet product was not identified. Accordingly, current U.S. product information here is limited to dosage forms that can be verified from authoritative records.
What can be verified now is:
- Injection: Cipla USA testosterone cypionate injection, 200 mg/mL, intramuscular, prescription only and Schedule III in the United States.
- Topical solution: Cipla USA testosterone topical solution, 30 mg per 1.5 mL application unit in the current DailyMed product data.
Cipla has also historically developed testosterone transdermal products. For example, older official Cipla annual reports referenced Androfil testosterone transdermal gel and later U.S. launch activity involving testosterone transdermal solution. Those historical references help explain the company’s longer relationship with androgen products, but they should not be used as evidence that an old brand remains current.
Product Names, Strengths and Markets
For a current U.S. Cipla testosterone product, the most reliable identification method is to use the generic name, dosage form, concentration, NDC, and current label rather than an old marketing name.
The current testosterone cypionate injection record includes Cipla USA NDCs in the 69097-802 series and a concentration of 200 mg/mL. The current topical solution record uses NDC 69097-363-44 and lists 30 mg testosterone per 1.5 mL.
Older DailyMed records also show that Cipla USA has had more than one testosterone cypionate NDC family over time. This is another reason not to rely on a single package photograph or an old article. Product records can be revised, relabeled, or replaced while search results continue to surface older identifiers.
How to Read a Current Cipla Testosterone Listing
A current testosterone listing should be read as a complete product record, not as a generic “Cipla testosterone” entry. For the Cipla USA testosterone cypionate injection, DailyMed identifies the route as intramuscular, the concentration as 200 mg/mL, the NDC family, the ANDA marketing category, and the controlled-substance schedule. The topical solution has a different NDC, formulation, application route, and label precautions.
That level of detail matters before comparing price or availability. A quote for a 1 mL single-dose vial cannot be meaningfully compared with a 10 mL multiple-dose vial or with a topical-solution package simply because all contain testosterone-related products. Package size and dosage form are part of the commercial product identity.
Controlled-Substance and Formulation Context
Current U.S. Cipla testosterone records identify these products as Schedule III controlled substances. That status is specific to the U.S. regulatory context and is another reason why testosterone access should not be compared with ordinary over-the-counter product searches.
The formulation also changes practical handling questions. An intramuscular injection and a topical solution differ in route, packaging, storage/use instructions, and safety precautions. The topical product’s current Medication Guide, for example, includes warnings about secondary skin transfer. Those differences support keeping the forms separate rather than creating a single “testosterone tablets/injections/gel” price list.
Pricing and Availability
There is no single reliable “Cipla testosterone price” that applies across products and markets. An injection vial and a topical solution are different products with different NDCs, package sizes, wholesalers, insurance treatment, cash prices, and pharmacy acquisition costs. U.S. retail prices can also vary by pharmacy and coverage.
A stable authoritative price source suitable for a durable manufacturer reference was not identified, so no fixed dollar range is published here. Older tablet-price figures are not used because they do not establish current product pricing.
A useful price inquiry should instead identify the exact product first: testosterone cypionate injection or topical solution, concentration, package size, NDC if available, prescription, and market. Current pharmacy pricing can then be checked at the time of dispensing. Regulatory approval does not guarantee that a particular pharmacy has the product in stock.
For the same reason, an online price attached only to the word “testosterone” is not a meaningful comparison unless the exact formulation and package are identified.
Testosterone Products vs ED Medicines
Testosterone products and PDE5 inhibitors belong to different medication categories. Sildenafil and tadalafil act as PDE5 inhibitors and appear in prescription products labeled for erectile dysfunction and other indications. Testosterone replacement products provide testosterone in specific formulations for patients whose diagnosis and treatment plan support their use.
A testosterone product should therefore not be compared with sildenafil or tadalafil as if the products were two brands of the same drug. The active ingredients, indications, monitoring requirements, controlled-substance status, and dosage forms are different.
This page does not recommend testosterone therapy for erectile dysfunction and does not suggest changing from one category to another. It exists to clarify the product relationships for users researching Cipla names before a prescription or purchase decision.
Regulatory Status
In the United States, the current Cipla USA testosterone cypionate and topical-solution records are prescription products listed in DailyMed under specific ANDAs. The testosterone products are controlled substances under Schedule III.
That product-specific status is more meaningful than saying “Cipla testosterone is FDA approved” as a blanket statement. Different formulations have different applications, labels, NDCs, and marketing histories. An older Cipla testosterone product or a product sold in another country needs its own current regulatory check.
The same principle applies internationally. A product appearing in Cipla historical materials does not establish that it is registered or commercially available today in the United States, United Kingdom, European Union, Australia, or another market.
Other Cipla Sexual-Health Products
Cipla’s current therapy information confirms continuing activity in urology and sexual-dysfunction-related care. The manufacturer is also associated with PDE5-inhibitor products containing sildenafil and tadalafil, which have separate product-reference pages on this site.
For sildenafil-specific product names, U.S. generic strengths, and historical Silagra context, see Cipla sildenafil products. For tadalafil, including the distinction between ED/BPH products and the PAH-labeled “Cipla 526” product, see Cipla tadalafil products.
Those pages should not be used to infer testosterone treatment. Their purpose is product identification and market context within separate medication categories.
More About Cipla
For the manufacturer-level overview, including Cipla’s broader therapeutic areas and other product groups, return to Cipla Limited.
When researching a specific testosterone product, the most useful information to collect is the exact generic name, dosage form, concentration, NDC or market registration number, and country. That allows current product, regulatory, and price questions to be answered without relying on stale brand or pricing claims.
Reviewed by: Dr. Nancy Ann Curosh